"Hepacivirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
| Descriptor ID |
D016174
|
| MeSH Number(s) |
B04.450.410 B04.820.250.475
|
| Concept/Terms |
Hepacivirus- Hepacivirus
- Hepaciviruses
- Hepatitis C-Like Viruses
- Hepatitis C Like Viruses
- Hepatitis C-Like Virus
|
Below are MeSH descriptors whose meaning is more general than "Hepacivirus".
Below are MeSH descriptors whose meaning is more specific than "Hepacivirus".
This graph shows the total number of publications written about "Hepacivirus" by people in this website by year, and whether "Hepacivirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 3 | 1 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 5 | 0 | 5 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 4 | 9 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 4 | 6 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepacivirus" by people in Profiles.
-
Cohen S, Cowan V, Rohan V, Pavlakis M, Curry MP, Adler JT, Safa K, Fleishman A, Shenkel J, Rodrigue JR. Willingness of Kidney and Liver Transplant Candidates to Receive HCV-Infected Organs. J Surg Res. 2022 Oct; 278:342-349.
-
Diaz-Castrillon CE, Huckaby LV, Witer L, Pope NH, Katz MR, Baliga PK, Kilic A. National trends and outcomes of heart-kidney transplantation using hepatitis C positive donors. Clin Transplant. 2022 04; 36(4):e14581.
-
Behnke C, Nissim O, Simerlein W, Beeker K, Tarleton JL, Lazenby GB. Quality improvement to evaluate and provide treatment for chronic hepatitis C postpartum. J Am Pharm Assoc (2003). 2022 May-Jun; 62(3):864-869.
-
Ball LE, Agana B, Comte-Walters S, Rockey DC, Masur H, Kottilil S, Meissner EG. Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. J Viral Hepat. 2021 11; 28(11):1614-1623.
-
Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021 04; 160(5):1502-1520.e1.
-
Orr C, Xu W, Masur H, Kottilil S, Meissner EG. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.
-
Mattingly TJ, Love BL, Khokhar B. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. Pharmacoeconomics. 2020 09; 38(9):927-939.
-
Chung JH, Hong SH, Seo N, Kim TS, An HJ, Lee P, Shin EC, Kim HM. Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency. Cytokine. 2020 01; 125:154833.
-
Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hassan MA, Pearlman BL, Hinestrosa F, Jacobson IM, Morelli G, Peter JA, Vainorius M, Michael LC, Fried MW, Wang GP, Lu W, Larsen L, Nelson DR. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 2019 12; 157(6):1506-1517.e1.
-
Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis. 2018 08 31; 67(6):878-880.